• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AXP
Click for more information
0.00% 0.2¢

AXP ENERGY LIMITED - Announcements

Market Cap $5.824M  ! watchlist Created with Sketch. Add to my watchlist

AXP Energy Ltd. is an oil and gas production and development company. The Company’s... AXP Energy Ltd. is an oil and gas production and development company. The Company’s segments are defined by geographic area within its Oil & Gas basins in the United States: Appalachian Basin, Denver-Julesburg Basin, Illinois Basin, and Corporate and other. The Appalachian Basin is situated primarily in the Eastern part of Kentucky, Western Virginia and North-Eastern part of Tennessee; these assets are situated in a well-defined gas producing area of the Appalachian Basin. The Denver-Julesburg Basin assets are situated in the historic Florence oilfield and are geologically defined by the Canon City Embayment. The Illinois Basin is spread across Western Kentucky, situated in the heart and prolific section of the basin. Its formations of interest include the Palestine, Waltersburg, Tar Springs, Hardinsburg, Jackson, St. Genevieve, O’Hara, McClosky, Warsaw and Fort Payne. The Company has primary operations in Kentucky, Illinois, Indiana and Colorado.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
Filters [Clear]
  • Price Sensitive: Yes
AXP S&P DJI Announces March 2019 Quarterly RebalancePRICE SENSITIVE08/03/19
AXP Preliminary Final Report and Consolidated Financial AccountsPRICE SENSITIVE28/02/19
AXP Appendix 4CPRICE SENSITIVE30/01/19
AXP 30 September 2018 Form 10QPRICE SENSITIVE01/11/18
AXP Appendix 4CPRICE SENSITIVE31/10/18
AXP Results of Special Meeting of StockholdersPRICE SENSITIVE25/10/18
AXP New AeroForm Study on Radiation Therapy Treatment MethodPRICE SENSITIVE17/10/18
AXP Latest AeroForm Study Confirms Treatment SuccessPRICE SENSITIVE04/10/18
AXP Final Notice of Special MeetingPRICE SENSITIVE04/10/18
AXP Preliminary Notice of Special MeetingPRICE SENSITIVE24/09/18
AXP Appendix 4D Half Yearly ReportPRICE SENSITIVE31/08/18
AXP Successful Closing of A$20.3m Rights Offering & US PlacementPRICE SENSITIVE27/08/18
AXP Notice of DispatchPRICE SENSITIVE13/08/18
AXP Form 8K Entry into a material definitive agreementPRICE SENSITIVE09/08/18
AXP Registration Statement on Form S 1 Declared EffectivePRICE SENSITIVE07/08/18
AXP AirXpanders announces raising of approximately A$20.3mPRICE SENSITIVE03/08/18
AXP 30 June 2018 Form 10QPRICE SENSITIVE31/07/18
AXP Appendix 4CPRICE SENSITIVE31/07/18
AXP Trading haltPRICE SENSITIVE31/07/18
AXP AirXpanders Announces New CEOPRICE SENSITIVE12/06/18
AXP Removal of FOR US designation from CDIsPRICE SENSITIVE15/05/18
AXP Appendix 4CPRICE SENSITIVE27/04/18
AXP AirXpanders Announces Management ChangesPRICE SENSITIVE09/04/18
AXP Preliminary Final Report and Consolidated Financial AccountsPRICE SENSITIVE28/02/18
AXP Appendix 4CPRICE SENSITIVE25/01/18
AXP 30 September 2017 Form 10QPRICE SENSITIVE10/11/17
AXP Appendix 4CPRICE SENSITIVE20/10/17
AXP New data presented on use of AeroForm Tissue Expander SystemPRICE SENSITIVE09/10/17
AXP Completion of Manufacturing Transfer to Costa RicaPRICE SENSITIVE28/09/17
AXP Appendix 4D Half Yearly ReportPRICE SENSITIVE10/08/17
AXP AirXpanders Completes US$15 Million Debt FinancingPRICE SENSITIVE07/08/17
AXP Appendix 4CPRICE SENSITIVE26/07/17
AXP Update on AeroForm Availability in US Medical InstitutionsPRICE SENSITIVE09/06/17
AXP Appendix 4CPRICE SENSITIVE28/04/17
AXP Update on US Commercial LaunchPRICE SENSITIVE04/04/17
AXP S&P DJ Indices Announces March Quarterly RebalancePRICE SENSITIVE10/03/17
AXP Preliminary Final Report and Consolidated Financial AccountsPRICE SENSITIVE28/02/17
AXP Reinstatement to Official QuotationPRICE SENSITIVE27/01/17
AXP Appendix 4CPRICE SENSITIVE27/01/17
AXP AirXpanders Raises A$45 Million in Private PlacementPRICE SENSITIVE27/01/17
AXP Suspension from Official QuotationPRICE SENSITIVE25/01/17
AXP Trading HaltPRICE SENSITIVE23/01/17
AXP First Commercial U.S. Procedure for AeroFormPRICE SENSITIVE17/01/17
AXP FDA de novo clearance for AeroForm Tissue Expander SystemPRICE SENSITIVE22/12/16
AXP Pivotal Trial Data for AirXpanders PublishedPRICE SENSITIVE29/11/16
AXP Appendix 4C-AXP.AX PRICE SENSITIVE21/10/16
AXP Positive Results Highlighted at ASPS Annual Meeting-AXP.AX PRICE SENSITIVE26/09/16
AXP Appendix 4D Half Year Report and Accounts-AXP.AX PRICE SENSITIVE28/08/16
AXP Appendix 4D Half Year Report and Accounts-AXP.AX PRICE SENSITIVE25/08/16
AXP Appendix 4C - quarterly-AXP.AX PRICE SENSITIVE22/07/16
AXP AirXpanders Raises A$20 Million in Private Placement-AXP.AX PRICE SENSITIVE08/06/16
AXP Trading Halt-AXP.AX PRICE SENSITIVE06/06/16
AXP Appendix 4C - quarterly-AXP.AX PRICE SENSITIVE26/04/16
AXP Preliminary Final Report and Full Year Statutory AccountsPRICE SENSITIVE26/02/16
AXP Appendix 4C - quarterlyPRICE SENSITIVE29/01/16
AXP AirXpanders to use de novo process for AeroFormPRICE SENSITIVE13/11/15
AXP Appendix 4C - quarterlyPRICE SENSITIVE29/10/15
AXP AirXpanders presents successful XPAND pivotal trial dataPRICE SENSITIVE20/10/15
AXP AeroForm Australian Launch UpdatePRICE SENSITIVE07/10/15
AXP AirXpanders submits FDA 510(k) filing for AeroFormPRICE SENSITIVE01/09/15
AXP Appendix 4D and Half Year Financial ResultsPRICE SENSITIVE31/08/15
AXP AirXpanders XPAND Pivotal Trial Meets Primary EndpointPRICE SENSITIVE25/08/15
AXP Appendix 4C - quarterlyPRICE SENSITIVE29/07/15
AXP ASX Market Release - Pre-quotation disclosurePRICE SENSITIVE19/06/15
AXP ASX Market Release - Admission to Official ListPRICE SENSITIVE19/06/15
AXP S&P DJI Announces March 2019 Quarterly Rebalance
08/03/19PRICE SENSITIVE
AXP Preliminary Final Report and Consolidated Financial Accounts
28/02/19PRICE SENSITIVE
AXP Appendix 4C
30/01/19PRICE SENSITIVE
AXP 30 September 2018 Form 10Q
01/11/18PRICE SENSITIVE
AXP Appendix 4C
31/10/18PRICE SENSITIVE
AXP Results of Special Meeting of Stockholders
25/10/18PRICE SENSITIVE
AXP New AeroForm Study on Radiation Therapy Treatment Method
17/10/18PRICE SENSITIVE
AXP Latest AeroForm Study Confirms Treatment Success
04/10/18PRICE SENSITIVE
AXP Final Notice of Special Meeting
04/10/18PRICE SENSITIVE
AXP Preliminary Notice of Special Meeting
24/09/18PRICE SENSITIVE
AXP Appendix 4D Half Yearly Report
31/08/18PRICE SENSITIVE
AXP Successful Closing of A$20.3m Rights Offering & US Placement
27/08/18PRICE SENSITIVE
AXP Notice of Dispatch
13/08/18PRICE SENSITIVE
AXP Form 8K Entry into a material definitive agreement
09/08/18PRICE SENSITIVE
AXP Registration Statement on Form S 1 Declared Effective
07/08/18PRICE SENSITIVE
AXP AirXpanders announces raising of approximately A$20.3m
03/08/18PRICE SENSITIVE
AXP 30 June 2018 Form 10Q
31/07/18PRICE SENSITIVE
AXP Appendix 4C
31/07/18PRICE SENSITIVE
AXP Trading halt
31/07/18PRICE SENSITIVE
AXP AirXpanders Announces New CEO
12/06/18PRICE SENSITIVE
AXP Removal of FOR US designation from CDIs
15/05/18PRICE SENSITIVE
AXP Appendix 4C
27/04/18PRICE SENSITIVE
AXP AirXpanders Announces Management Changes
09/04/18PRICE SENSITIVE
AXP Preliminary Final Report and Consolidated Financial Accounts
28/02/18PRICE SENSITIVE
AXP Appendix 4C
25/01/18PRICE SENSITIVE
AXP 30 September 2017 Form 10Q
10/11/17PRICE SENSITIVE
AXP Appendix 4C
20/10/17PRICE SENSITIVE
AXP New data presented on use of AeroForm Tissue Expander System
09/10/17PRICE SENSITIVE
AXP Completion of Manufacturing Transfer to Costa Rica
28/09/17PRICE SENSITIVE
AXP Appendix 4D Half Yearly Report
10/08/17PRICE SENSITIVE
AXP AirXpanders Completes US$15 Million Debt Financing
07/08/17PRICE SENSITIVE
AXP Appendix 4C
26/07/17PRICE SENSITIVE
AXP Update on AeroForm Availability in US Medical Institutions
09/06/17PRICE SENSITIVE
AXP Appendix 4C
28/04/17PRICE SENSITIVE
AXP Update on US Commercial Launch
04/04/17PRICE SENSITIVE
AXP S&P DJ Indices Announces March Quarterly Rebalance
10/03/17PRICE SENSITIVE
AXP Preliminary Final Report and Consolidated Financial Accounts
28/02/17PRICE SENSITIVE
AXP Reinstatement to Official Quotation
27/01/17PRICE SENSITIVE
AXP Appendix 4C
27/01/17PRICE SENSITIVE
AXP AirXpanders Raises A$45 Million in Private Placement
27/01/17PRICE SENSITIVE
AXP Suspension from Official Quotation
25/01/17PRICE SENSITIVE
AXP Trading Halt
23/01/17PRICE SENSITIVE
AXP First Commercial U.S. Procedure for AeroForm
17/01/17PRICE SENSITIVE
AXP FDA de novo clearance for AeroForm Tissue Expander System
22/12/16PRICE SENSITIVE
AXP Pivotal Trial Data for AirXpanders Published
29/11/16PRICE SENSITIVE
AXP Appendix 4C-AXP.AX
21/10/16PRICE SENSITIVE
AXP Positive Results Highlighted at ASPS Annual Meeting-AXP.AX
26/09/16PRICE SENSITIVE
AXP Appendix 4D Half Year Report and Accounts-AXP.AX
28/08/16PRICE SENSITIVE
AXP Appendix 4D Half Year Report and Accounts-AXP.AX
25/08/16PRICE SENSITIVE
AXP Appendix 4C - quarterly-AXP.AX
22/07/16PRICE SENSITIVE
AXP AirXpanders Raises A$20 Million in Private Placement-AXP.AX
08/06/16PRICE SENSITIVE
AXP Trading Halt-AXP.AX
06/06/16PRICE SENSITIVE
AXP Appendix 4C - quarterly-AXP.AX
26/04/16PRICE SENSITIVE
AXP Preliminary Final Report and Full Year Statutory Accounts
26/02/16PRICE SENSITIVE
AXP Appendix 4C - quarterly
29/01/16PRICE SENSITIVE
AXP AirXpanders to use de novo process for AeroForm
13/11/15PRICE SENSITIVE
AXP Appendix 4C - quarterly
29/10/15PRICE SENSITIVE
AXP AirXpanders presents successful XPAND pivotal trial data
20/10/15PRICE SENSITIVE
AXP AeroForm Australian Launch Update
07/10/15PRICE SENSITIVE
AXP AirXpanders submits FDA 510(k) filing for AeroForm
01/09/15PRICE SENSITIVE
AXP Appendix 4D and Half Year Financial Results
31/08/15PRICE SENSITIVE
AXP AirXpanders XPAND Pivotal Trial Meets Primary Endpoint
25/08/15PRICE SENSITIVE
AXP Appendix 4C - quarterly
29/07/15PRICE SENSITIVE
AXP ASX Market Release - Pre-quotation disclosure
19/06/15PRICE SENSITIVE
AXP ASX Market Release - Admission to Official List
19/06/15PRICE SENSITIVE
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
0.2¢ 		Change
0.000(0.00%) 		Mkt cap ! $5.824M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
33 42453992 0.1¢
 

Sellers (Offers)

Price($) Vol. No.
0.2¢ 88974573 57
View Market Depth
Last trade - 16.12pm 22/11/2024 (20 minute delay) ?
AXP (ASX) Chart

Top Stories

Scientific conference spotlights PYC's work on blindness disease treatment

PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore
Week 47 Wrap: HotCopper users' most watched; Brent lifts on Putin's scary letter; RFK dents CSL Welcome to the end of another week. Let's start with what HotCopper users have been watching and discussing.
HotCopper Highlights: Your most watched stocks for Week 47, 2024 In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
Dale Gillham's weekly wrap: Sigma-Chemist Warehouse merger creates pharma powerhouse The $8.8 billion dollar merger between Sigma Healthcare and Chemist Warehouse is poised to reshape the Australian pharmacy landscape, consolidating power in the hands of two industry giants. But what does this mean for Australians @ greater access to cheaper medicines or the loss of small, commun...
MinRes's Ellison knows he screwed up – for that reason, hunt for new Chair to be sped up Who the MinRes Board has decided to move on faster may or may not be amusing, depending on how much you've lost.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.